Spurdle AB - Search Results

1

CYP17 promotor polymorphism and ovarian cancer risk.

Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a. Int J Cancer. 2000. PMID: 10760835

2

Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years.

Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. J Natl Cancer Inst. 1999 Jun 2;91(11):961-6. doi: 10.1093/jnci/91.11.961. J Natl Cancer Inst. 1999. PMID: 10359549

3

Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.

Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 Sep 1;87(5):637-43. Int J Cancer. 2000. PMID: 10925355

4

CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.

Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G. Spurdle AB, et al. J Natl Cancer Inst. 2000 Oct 18;92(20):1674-81. doi: 10.1093/jnci/92.20.1674. J Natl Cancer Inst. 2000. PMID: 11036113

5

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 Jan;22(1):67-72. doi: 10.1093/carcin/22.1.67. Carcinogenesis. 2001. PMID: 11159743

6

The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.

Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Mol Carcinog. 2001 Jan;30(1):71-8. doi: 10.1002/1098-2744(200101)30:1<71::aid-mc1015>3.0.co;2-9. Mol Carcinog. 2001. PMID: 11255266

7

No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 May;22(5):717-21. doi: 10.1093/carcin/22.5.717. Carcinogenesis. 2001. PMID: 11323389

8

A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.

Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. Wang WW, et al. Among authors: spurdle ab. Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11535547

9

The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.

Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, Mann GJ, Hopper JL, Sambrook JF, Chenevix-Trench G; Australian Breast Cancer Family Study; Kathleen Cuningham Foundation for Research into Familial Breast Cancer. Marsh A, et al. Among authors: spurdle ab. Breast Cancer Res. 2001;3(5):346-9. doi: 10.1186/bcr319. Epub 2001 Jul 17. Breast Cancer Res. 2001. PMID: 11597326 Free PMC article.

10

The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G. Spurdle AB, et al. Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1287-93. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11751447

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

475 results

Search Page

Filters